Nomura: Gives CSPC PHARMA a target price of HKD 8.02 with a rating of "Buy"
Nomura released a research report stating that it has set a target price of HKD 8.02 for CSPC PHARMA, with a rating of "Buy." The report indicates that CSPC PHARMA's performance in the first quarter of 2025 was weak, with revenue decreasing by 21.9% year-on-year to RMB 7 billion (the same below), lower than the expected RMB 8.8 billion, and profit decreasing by 8.4% year-on-year to RMB 1.5 billion, also below the expected RMB 2.4 billion. The gross profit margin decreased by 5.2 percentage points year-on-year to 67.1%, with the gross profit margin for pharmaceutical sales being lower than the firm's expectations, mainly due to adverse changes in the product mix
According to the Zhitong Finance APP, Nomura has released a research report stating that it has set a target price of HKD 8.02 for CSPC PHARMA (01093) with a rating of "Buy." The report indicates that CSPC PHARMA's performance in the first quarter of 2025 was weak, with revenue decreasing by 21.9% year-on-year to RMB 7 billion (the same below), lower than the expected RMB 8.8 billion, and profit decreasing by 8.4% year-on-year to RMB 1.5 billion, also below the expected RMB 2.4 billion. The gross profit margin decreased by 5.2 percentage points year-on-year to 67.1%, with the gross profit margin of pharmaceutical sales falling below the bank's expectations, mainly due to adverse changes in the product mix
